Cargando…

Glucocorticoid-Induced Fatty Liver Disease

Glucocorticoids (GCs) are commonly used at high doses and for prolonged periods (weeks to months) in the treatment of a variety of diseases. Among the many side effects are increased insulin resistance with disturbances in glucose/insulin homeostasis and increased deposition of lipids (mostly trigly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahimi, Leili, Rajpal, Aman, Ismail-Beigi, Faramarz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171875/ https://www.ncbi.nlm.nih.gov/pubmed/32368109 http://dx.doi.org/10.2147/DMSO.S247379

Ejemplares similares

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
por: Gharaibeh, Naser Eddin, et al.
Publicado: (2019)

Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature
por: Rahimi, Leili, et al.
Publicado: (2020)

Beta‐cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?
por: Sayyed Kassem, Laure, et al.
Publicado: (2023)

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Taheri, Hoda, et al.
Publicado: (2020)

Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial
por: Attaran, Fereshte, et al.
Publicado: (2023)

Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis
por: Bazwinsky-Wutschke, Ivonne, et al.
Publicado: (2019)

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Chehrehgosha, Haleh, et al.
Publicado: (2021)

The Mechanism of the Calorigenic Action of Thyroid Hormone : Stimulation of Na(+) + K(+)-activated adenosinetriphosphatase activity
por: Ismail-Beigi, Faramarz, et al.
Publicado: (1971)

A View Beyond HbA1c: Role of Continuous Glucose Monitoring
por: Chehregosha, Haleh, et al.
Publicado: (2019)

Glucocorticoid Replacement for Adrenal Insufficiency and the Development of Non-Alcoholic Fatty Liver Disease
por: Meyer, Gesine, et al.
Publicado: (2023)

Prolonged Exposure to Insulin Inactivates Akt and Erk(1/2) and Increases Pancreatic Islet and INS1E β-Cell Apoptosis
por: Rachdaoui, Nadia, et al.
Publicado: (2018)

Glucocorticoid‐induced osteoporosis in rheumatic diseases
por: Pereira, Rosa Maria Rodrigues, et al.
Publicado: (2010)

Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease
por: Pirmoazen, Amir M., et al.
Publicado: (2020)

SAT-483 Levothyroxine Absorption Test: A Potential Therapeutic Tool for Levothyroxine Malabsorption
por: Arora, Tanureet, et al.
Publicado: (2020)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

SAT-391 Perioperative Glucocorticoid Therapy for Patients with Adrenal Insufficiency: Dosing Based on Hydrocortisone Pharmacokinetic Data
por: Rahhal, Marie-Noel, et al.
Publicado: (2019)

Drug-induced Fatty Liver Disease: Pathogenesis and Treatment
por: Kolaric, Tea Omanovic, et al.
Publicado: (2021)

Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease
por: Massart, Julie, et al.
Publicado: (2022)

Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?
por: Plaz Torres, Maria Corina, et al.
Publicado: (2020)

Glucocorticoid-induced osteoporosis: an update
por: Compston, Juliet
Publicado: (2018)

From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
por: Kang, Seong Hee, et al.
Publicado: (2021)

Role of bioactive fatty acids in nonalcoholic fatty liver disease
por: Juárez-Hernández, Eva, et al.
Publicado: (2016)

Non-alcoholic fatty liver disease and liver secretome
por: Khan, Muhammad Sohaib, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease and non-liver comorbidities
por: Manikat, Richie, et al.
Publicado: (2023)

Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease
por: Torres, Jorge-Luis, et al.
Publicado: (2018)

Glucocorticoid-Induced Leucine Zipper (GILZ) in Cardiovascular Health and Disease
por: Cappetta, Donato, et al.
Publicado: (2021)

History of Nonalcoholic Fatty Liver Disease
por: Lonardo, Amedeo, et al.
Publicado: (2020)

Sirtuins and nonalcoholic fatty liver disease
por: Nassir, Fatiha, et al.
Publicado: (2016)

Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Problems and Challenges Associated with Renaming Non-alcoholic Fatty Liver Disease to Metabolic Associated Fatty Liver Disease
por: Zeng, Minghui, et al.
Publicado: (2023)

The Role of Glucocorticoids in Inflammatory Diseases
por: Reichardt, Sybille D., et al.
Publicado: (2021)

Update on Glucocorticoid Induced Osteoporosis
por: Cho, Soo-Kyung, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers
por: Anavi, Sarit, et al.
Publicado: (2017)

Natural Product Heme Oxygenase Inducers as Treatment for Nonalcoholic Fatty Liver Disease
por: Stec, David E., et al.
Publicado: (2020)

Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD)
por: Chen, Qian, et al.
Publicado: (2017)

Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity
por: Massart, Julie, et al.
Publicado: (2017)

Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Ramai, Daryl, et al.
Publicado: (2021)

Liver-derived metabolites as signaling molecules in fatty liver disease
por: Keles, Umur, et al.
Publicado: (2022)

Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes
por: Alomari, Mohammad, et al.
Publicado: (2023)

Pediatric Fatty Liver and Obesity: Not Always Just a Matter of Non-Alcoholic Fatty Liver Disease
por: Alfani, Renata, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n57mbmt2oqmbacrd6kvr8c6mn1